Nuancing the Benefit of Circulating Tumor DNA
August 10, 2022

In the context of clinical trial data and personal experience, experts weigh the value of circulating tumor DNA as a tool in cancer care.

Clinical Trial Data on Use of ctDNA Assays
August 10, 2022

Experts share their perspective on clinical trial data driving the use of circulating tumor DNA in various settings of cancer care.

Sexual Dysfunction Poses Significant Issue for Women With Lung Cancer
August 10, 2022

Experts indicated that 77% of women with lung cancer who were surveyed reported having moderate to severe sexual dysfunction.

Noninferior OS End Point Met With First-line Tislelizumab Vs Sorafenib in Unresectable HCC
August 10, 2022

The phase 3 RATIONALE 301 trial examining first-line tislelizumab vs sorafenib in unresectable hepatocellular carcinoma met the primary end point of noninferior overall survival.

Positive Results With Sitravatinib Plus Tislelizumab Noted in PD-L1+ Advanced Squamous NSCLC
August 10, 2022

Patients with advanced PD-L1–positive non–small cell lung cancer and squamous histology who were treated with sitravatinib plus tiselizumab had promising antitumor activity.

Paul G. Richardson, MD, On Using MRD to Inform Choice Between Systemic Therapy and Transplant in Newly Diagnosed Myeloma
August 10, 2022

Paul G. Richardson, MD, looks at MRD data from the DETERMINATION study for its potential to guide treatment selection in newly diagnosed multiple myeloma.

Oncology Peer Review On-The-Go: Current Treatments in Marginal Zone Lymphoma
August 09, 2022

Juan Pablo Alderuccio, MD, spoke with CancerNetwork® about a review article on the treatment of marginal zone lymphoma published in the journal ONCOLOGY®.

Efficacy, Safety With Datopotamab Deruxtecan Plus Pembrolizumab Regimen Observed in Advanced NSCLC
August 09, 2022

TROPION-Lung02 trial provides evidence of datopotamab deruxtecan and pembrolizumab efficacy in patients with advanced/metastatic non–small cell lung cancer and no actionable genomic alterations.

OS End Point Met in Phase 3 FRESCO-2 Trial Examining Fruquintinib in Metastatic CRC
August 09, 2022

Overall survival, the primary end point of the phase 3 FRESCO-2 trial, was met when patients were given fruquintinib vs placebo for advanced refractory metastatic colorectal cancer.

Favorable OS Outcomes Observed With Front-Line Durvalumab Plus Tremelimumab in Metastatic NSCLC
August 09, 2022

Durvalumab plus tremelimumab in the first-line setting yielded improved overall survival vs chemotherapy in patients with metastatic non–small cell lung cancer.